Partnering

AstraZeneca has partnered with Bavarian Nordic, a Kvistgaard, Denmark-based biopharmaceutical company, to investigate Bavarian’s targeted immunotherapy candidate, CV301, and durvalumab, AstraZeneca’s programmed death ligand-1 (PD-L1) inhibitor, in combination with maintenance…

Kite Pharma, Gilead Sciences’ cell-therapy subsidiary, and Sangamo Therapeutics, a Richmond, California-based biotechnology company, have partnered to use Sangamo’s zinc finger nuclease (ZFN) technology platform for developing ex vivo cell…

AstraZeneca and Ionis Pharmaceuticals, a Carlsbad, California-based pharmaceutical company, have formed an agreement in which AstraZeneca will license Ionis’ IONIS-AZ5-2.5Rx, an antisense drug. IONIS-AZ5-2.5Rx was discovered by Ionis, and it…

Takeda Pharmaceutical Company has formed a pact and multi-program option agreement with Wave Life Sciences, a Cambridge, Massachusetts-headquartered biopharmaceutical company, to develop antisense oligonucleotides for genetically defined neurological diseases. The…

AbbVie and Voyager Therapeutics, a Cambridge, Massachusetts-headquartered clinical-stage gene-therapy company, have partnered to develop and commercialize vectorized antibodies directed against tau, a protein in the brain that promotes cellular stability,…

Bristol-Myers Squibb (BMS) and Nektar Therapeutics, a biopharmaceutical company, have partnered to develop and commercialize Nektar’s lead immuno-oncology drug candidate in combination with BMS’ immuno-oncology drugs, Opdivo (nivolumab) and Opdivo…

Roivant Sciences, a Basel, Switzerland globally-headquartered biopharmaceutical company, and Poxel SA, a Lyon, France-based biopharmaceutical company developing treatments for metabolic disorders, have signed a development and license agreement for imeglimin,…

Takeda Pharmaceutical and Fujifilm have partnered to develop regenerative medicine therapies using cardiomyocytes derived from induced pluripotent stem cells (iPSC) for treating heart failure. Takeda and Fujifilm signed a contract…

Rexahn Pharmaceuticals, a Rockville, Maryland-headquartered clinical-stage biopharmaceutical company developing therapeutics for treating cancer, has formed a pact with Zhejiang Haichang Biotechnology, a Zhejiang, China-headquartered biopharmaceutical company, to develop Archexin (RX-0201)…

Seattle Genetics, a Bothell, Washington-headquartered biopharmaceutical company, and Pieris Pharmaceuticals, a Boston, Massachusetts-headquartered clinical-stage biopharmaceutical company, have partnered to develop multiple targeted bispecific immuno-oncology treatments for solid tumors and blood…